Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, ABVX, MLYS, RVMD, PCVX, and represent 69.21% of Caligan Partners's stock portfolio.
- Added to shares of these 10 stocks: MLYS (+$83M), PCVX (+$79M), TNGX (+$33M), XENE (+$29M), MAZE (+$23M), RAPT (+$22M), INBX (+$19M), RVMD (+$18M), VOR (+$10M), IVA (+$9.3M).
- Started 8 new stock positions in RAPT, SPRB, TNGX, ELDN, PCVX, MAZE, IVA, VOR.
- Reduced shares in these 5 stocks: AGIO (-$55M), EOLS (-$25M), MRUS (-$20M), SLS, AURA.
- Sold out of its positions in AURA, EOLS, SLS, MRUS.
- Caligan Partners was a net buyer of stock by $237M.
- Caligan Partners has $1.2B in assets under management (AUM), dropping by 59.11%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 21 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 23.1 | $280M | 8.1M | 34.49 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 16.1 | $196M | 1.5M | 134.85 |
|
|
| Mineralys Therapeutics (MLYS) | 15.1 | $184M | +82% | 5.1M | 36.29 |
|
| Revolution Medicines (RVMD) | 8.4 | $102M | +20% | 1.3M | 79.65 |
|
| Vaxcyte (PCVX) | 6.5 | $79M | NEW | 1.7M | 46.14 |
|
| Exelixis (EXEL) | 5.6 | $68M | 1.6M | 43.83 |
|
|
| Adma Biologics (ADMA) | 4.5 | $55M | +14% | 3.0M | 18.24 |
|
| Xenon Pharmaceuticals (XENE) | 4.1 | $49M | +147% | 1.1M | 44.82 |
|
| Inhibrx Biosciences (INBX) | 3.1 | $37M | +100% | 474k | 79.00 |
|
| Tango Therapeutics (TNGX) | 2.7 | $33M | NEW | 3.7M | 8.86 |
|
| Tyra Biosciences (TYRA) | 2.0 | $25M | +35% | 944k | 26.29 |
|
| Maze Therapeatics (MAZE) | 1.9 | $23M | NEW | 550k | 41.43 |
|
| Rapt Therapeutics Com New (RAPT) | 1.8 | $22M | NEW | 644k | 33.87 |
|
| Avalo Therapeutics Com New (AVTX) | 1.3 | $16M | +5% | 882k | 18.16 |
|
| Anika Therapeutics (ANIK) | 1.1 | $14M | 1.4M | 9.61 |
|
|
| Vor Biopharma Com New (VOR) | 0.8 | $10M | NEW | 925k | 10.77 |
|
| Inventiva Sa Ads (IVA) | 0.8 | $9.3M | NEW | 2.0M | 4.65 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.6 | $7.7M | 924k | 8.31 |
|
|
| Agios Pharmaceuticals Call Option (AGIO) | 0.2 | $2.4M | -95% | 90k | 27.22 |
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $1.8M | NEW | 21k | 87.11 |
|
| Eledon Pharmaceuticals (ELDN) | 0.1 | $840k | NEW | 556k | 1.51 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2025 Q4 filed Feb. 17, 2026
- Caligan Partners 2025 Q3 filed Nov. 14, 2025
- Caligan Partners 2025 Q2 filed Aug. 14, 2025
- Caligan Partners 2025 Q1 filed May 15, 2025
- Caligan Partners 2024 Q4 filed Feb. 14, 2025
- Caligan Partners 2024 Q3 filed Nov. 14, 2024
- Caligan Partners 2024 Q2 filed Aug. 14, 2024
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023